Compound blood pressure reducing prepn containing angiotonin converzyme inhibitor, calcium ion agonist and Estazolam

Abstract

The present invention provides one new kind of compound blood pressure reducing preparation containing angiotonin converzyme inhibitor, calcium ion agonist, Estazolam and pharmaceutically acceptable carrier. The angiotonin converzyme inhibitor is selected from Enalapril, Ramipril, Benalapril, Lisinopril, Acertil, etc. as well as their mixture; and the calcium ion agonist is selected from Nitrendpine, Amlodipine Besylate, Nifedipine, Felodipine, etc. as well as their mixture. The present invention utilizes the synergistic effect between different medicines to raise the blood pressure lowering effect, reduce side effect and improve the compliance of patient.

Description

technical field

[0001] The invention relates to a novel compound antihypertensive preparation, in particular to a compound antihypertensive preparation containing an angiotensin-converting enzyme inhibitor, a calcium ion antagonist and estazolam. Background technique

[0002] In recent years, most large-scale international authoritative hypertension clinical trials and hypertension treatment guidelines based on evidence-based medicine have shown that increasing the pressure reduction can actively and durably reduce the blood pressure of hypertensive patients to below 130 / 85 mm Hg ( It should be lowered to below 120 / 80 mm Hg), which can effectively reduce the damage of target organs such as heart, brain and kidney caused by high blood pressure, reduce or delay stroke, coronary heart disease, angina pectoris, myocardial infarction, renal failure, atherosclerosis, etc. It can reduce the occurrence of complications such as sclerosis and aneurysm, reduce the rate of cardiovascula...